Treatment results and prognostic factors for cervical cancer patients treated by radiochemotherapy with weekly cisplatin

Objective: This retrospective trial aims to report the treatment results of patients with locally advanced cervical cancer treated by concomitant radiochemotherapy with weekly cisplatin.

Methods: Between October 1999 and December 2003, 81 patients with FIGO Stages IB-IVA were treated at Ege University Faculty of Medicine Department of Radiation Oncology by radiochemotherapy with weekly cisplatin (40 mg/m2). Intracavitary high-dose rate brachytherapy was applied to 76 patients (93.8%) and five patients (6.2%) were treated with external radiotherapy alone. Early and late side-effects of the treatment were analyzed according to RTOG-EORTC criteria.

Results: Median age was 55 years and the most frequent histology was epidermoid carcinoma. Median follow-up time was 42 months. Five-year overall, disease-free and local relapse-free survival rates were 69%, 77%, and 82%, respectively. The presence of low Hgb level (< 12 g/dl), bulky tumor (> 4 cm), poor performance status, pelvic nodal involvement and limited early response to treatment had a significant impact on the local failure rate. Prognostic factors influencing disease-free survival were bulky tumor, performance status, pelvic nodal status, pretreatment Hgb level and limited early response to treatment. A significantly higher 5-year overall survival rate was observed in patients with good performance status, without pelvic nodal involvement, normal pretreatment Hgb level and complete response to treatment. Grade 3-4 side-effects were not observed in any patients. The most frequent acute side-effects were leukopenia, anemia, nausea and vomiting. Long-term side-effects were observed in 54% of patients.

Conclusion: This series suggests that radiochemotherapy with weekly cisplatin is an effective and a safe treatment in locally advanced cervical cancer.

Cervical cancer; Radiochemotherapy; Prognostic factors

[1] Parker S., Tong T., Bolden S. et al.: "Cancer statistic". CA Cancer J. Clin., 1996, 46, 5.

[2] Rose P.G., Bundy B.N.: "Chemo-radiation for locally advanced cervical cancer: does it help?". J. Clin. Oncol., 2002, 20, 891.

[3] Eifel P.: "Chemoradiotherapy in the treatment of cervical cancer". Semin. Radiat. Oncol., 2006, 16, 177.

[4] Rose P.G., Bundy B.N., Watkins J. et al.: "Concurrent cisplatinbased chemotherapy and radiotherapy for locally advanced cervical cancer". N. Engl. J. Med., 1999, 340, 1144.

[5] Keys H.M., Bundy B.N., Stehman F.B. et al.: "Cisplatin, radiation, and adjuvant hysterectomy for bulky Stage 1B cervical carci一 noma". N. Engl. J. Med., 1999, 340, 1154.

[6] Lanciano R., Calkins A., Bundy B.N. et al.: "Randomized comparison of weekly cisplatin or protracted venous infusion fluorouracil in combination with pelvic radiation in advanced cervix cancer: A Gynecologic Oncology Group Study". J. Clin. Oncol., 2005, 23, 8277.

[7] Peters W.A. 3'', Liu P.Y., Barrett R.J. 2"'et al.: "Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix". J. Clin. Oncol., 2000, 18, 1606.

[8] Pearcey RM., Brundage P., Drouin et al.: "Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix". J. Clin. Oncol., 2002, 20, 966.

[9] Morris M., Eifel P.J., Lu J. et al.: "Pelvic radiation with concurrent chemotherapy compared with pelvic and paraaortic radiation for high-risk cervical cancer". N. Engl. J. Med., 1999, 340, 1137.

[10] National Cancer Institute: NCI Clinical Announcement Bethesda, MD,United States Department of Health and Human Services, Public Health Service, National Institutes of Health, F ebruary 1999.

[11] Ozsaran Z., Yalman D., Y iiriit V. et al.: "Radiochemotherapy for patients with locally advanced cervical cancer: early results". Eur. J. Gynecol. Oncol., 2003, 24, 191.

[12] Perez C.A., Brady L.W.: "Overwiev". In: Principles and practice of Radiation Oncology.

[13] Chassagne D., Sismondi P., Horiot J.C. et al.: "A glossary for reporting complications of treatment in gynecological cancers". Radiother. Oncol., 1993, 26, 195.

[14] Green J.A., Kirwan J.M., Tierney J.F. et al.: "Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix". Lancet, 2001, 6, 781.

[15]Eifel P. J., Morris M., Wharton J.T. et al.: "The influence of tumor size and morphology on the outcome of patients with FIGO Stage 1B squamous cell carcinoma of the uterine cervix". Int. J. Radial. Oncol. Biol. Phys., 1994, 29, 9.

[16] Kovalic J.,，Perez C.A., Grigsby P. et al.:'The effect of volume of disease in patients with carcinoma of the uterine cervix". Int. J. Radiat. Oncol. Biol. Phys., 1991, 21, 905.

[17] Toita T., Nakano M., Higashi M. et al.: "Prognostic value of cervical size and pelvic lymph node status assessed by computed tomography for patients with uterine cervical cancer treated by radical radiation therapy". Int. J. Radial. Oncol. Biol. Phys., 1995, 33, 843.

[18] Pederson D., Sogaard H., Overgaard J. et al.: "Prognostic value of pretreatment factors in patients with locally advanced carcinoma of the uterine cervix treated by radiotherapy alone". Acta Oneal., 1995, 34, 787.

[19] Takeshi K., Katsuyuki K., Yoshiaki T. et al.: "Definitive radiotherapy combined with high-dose-rate brachytherapy for Stage III carcinoma of the uterine cervix: retrospective analysis of prognostic factors concerning patient characteritics and treatment parmeters". Int. J. Rad. Oncol. Biol. Phys., 1998, 41,319.

[20] Ito H., Kutuki S., Nisguchi I. et al.: "Radiotherapy for cervical cancer with high-dose rate brachytherapy: Correlation between tumor size,d ose and如lure". Radiother. Oncol.,1 994,3 1, 240.

[21] Fyles A.W., Pintilie M., Kirkbride P. et al.: "Prognostic factors in patients with cervix cancer treated by radiation therapy: Results of a multiple regression analysis". Radiother. Oncol., 1995, 35, 107.

[22] Mitsuhashi N., Takahashi M., Nozaki M. et al.: "Evaluation of external beam therapy and three brachytherapy fractions for carcinoma of the uterine cervix". Int. J. Radial. Oncol. Biol. Phys., 1994,29, 975.

[23] Serkiesi K., Badzioi A., Jassem J.: "Clinical relevance of hemoglobin level in cervical cancer patients administered definitive radiotherapy". Acta Oncol., 2006, 45, 695.

[24] Dunst J,, Kuhnt T,, Strauss H, et al,: "Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis", Int, J, Rad Onco/, Biol, Phys,, 2003, 56, 778,

[25] Sedlis A,B undy B.N.,R otman ML et al.: "A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with Stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study", GynecoL Oncol., 1999, 73, 177.

[26] Uno T, Ito H., Isobe K et al,: "Postoperative pelvic radiotherapy for cervical cancer patients with positive parametrial invasion" Gynecologic Oncology, 2005, 96, 335.

[27] Hardt N., Van Nagell R., Hanson M. et al,: "Radiation induced tumor regression as a prognostic factor in patients with invasive cervical cancer", Cancer, 1982, 48, 35.

[28] O'Hara K, Oki A, Tanaka YO, et al,: "Early determination of uterine cervical squamous cell carcinoma radioresponse identifies high- and low-response tumors". Int, J Rad Oncol. Biol, Phys., 2006, 64, 1179,

[29] Rakovitch E, Fyles A.W., Pint山e M. et aL: "Role of mitomycrn C in the development of late bowel toxicity.following chemoradiation for locally advanced carcinoma of the cervix", Int, J, Radial, Oncol, Biol, Phys,, 1997, 38, 979.

[30] Yalman D,,A rican A,,O zsaran Z, et al.: "Evaluation of morbidity after external radiotherapy and intracavitary brachytherapy in 771 patients with carcinoma of the uterine cervix or endometriurn", Eur. J Gynecol. Oncol., 2002, 23, 58.